discrepancies reported for 6 variants (Table 1) . First, the GLP-HEK assay uses qPCR to directly measure the amount of transfected plasmid DNA for transfection efficiency control [1] . The method employed by Oommen et al., an indirect measurement of co-transfected, secreted embryonic alkaline phosphatase (SEAP), may be inaccurate because overexpression of mutant α-galactosidase A (α-Gal A) can affect trafficking and secretion of SEAP [2] . Second, Oommen et al. used the relative activity (% of wild type) instead of absolute activity (nmol/mg/ h) to calculate the fold-increase in α-Gal A activity in response to migalastat, causing values for 4 variants to narrowly miss the amenability criteria (Table 1 ).
In conclusion, the concern over assay variability seems unfounded, since amenability to migalastat is determined in a single GLP-certified laboratory. We believe physicians can have a high level of confidence in the approved GLP-HEK assay, which identifies GLA variants with the potential to respond to migalastat. Of course, individual response will need to be assessed clinically. 
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